查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476400

全球疫苗契約製造市場：分析 - 按產品、類型、業務規模、流程、應用、最終用戶、地區和預測（截至 2030 年）

Vaccine Contract Manufacturing Market Forecasts to 2030 - Global Analysis By Product, Type, Scale of Operations, Process, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

預計2023年全球疫苗契約製造市場規模將達35.1億美元，預測期內複合年成長率為13.1%，2030年將達83億美元。疫苗契約製造涉及將疫苗生產委託給第三方製造商。製藥公司與受託製造廠商(CMO) 合作，利用他們的專業知識、設施和資源來高效、大規模地生產疫苗。這種方法可以實現及時且經濟高效的疫苗生產，同時使公司能夠專注於研究、開發和行銷。合約製造商遵守嚴格的品質標準和監管要求，以確保安全性和有效性。這種模式允許彈性的生產能力，並加速疫苗的供應，以滿足全球需求，特別是在疫情和緊急情況期間。

美國小兒科會2022年3月發布的資料顯示，美國有超過100萬人長期感染B型肝炎，而嬰兒時期感染B型肝炎的人一生中死亡的可能性更大有90%的機會患上肝癌等嚴重慢性疾病。

疫苗需求增加

疫苗需求的增加是推動疫苗契約製造市場成長的關鍵因素。隨著世界人口繼續優先考慮預防性醫療保健措施，對高效疫苗生產的需求不斷增加。疫苗契約製造為製藥公司提供了快速擴大生產以滿足不斷成長的需求的彈性。此外，將製造委託給專業設施使公司能夠專注於研發，加速疫苗創新。此外，與契約製造製造商合作簡化了生產流程，使我們能夠及時向市場提供疫苗。

品管挑戰

品管挑戰主要源自於嚴格遵守監管標準的需要、複雜的製造流程以及大量生產的要求。確保不同批次和設施的產品品質一致是一個主要障礙。此外，製造地分散在世界各地，使標準化和監控變得複雜。此外，在保持嚴格的品質標準的同時滿足生產期限的緊迫性可能會導致錯誤和疏忽。原料和設備的不一致加劇了這些挑戰。

全球疫苗需求

全球疫苗契約製造市場受到全球疫苗需求不斷成長的推動，帶來了巨大的商機。隨著COVID-19大流行的出現以及人們對疫苗接種興趣的增加，迫切需要擴大產能。該市場具有彈性、擴充性和成本效益的優勢，能夠快速應對新出現的感染疾病和大規模疫苗接種宣傳活動。外包疫苗生產可以降低與內部生產相關的風險，例如監管合規性和資源分配。

智慧財產權問題

許多疫苗受到專利、商標和商業機密的保護，這限制了生產方法和技術的取得。這為尋求進入市場或擴大生產規模的契約製造製造商造成了障礙。此外，智慧財產權糾紛可能會導致法律訴訟、延誤以及製造商成本增加。此外，智慧財產權法缺乏明確性和執行力可能會抑制新疫苗生產技術的創新和投資。透過明確的授權協議和有效的智慧財產權保護機制解決這些問題對於確保公平獲得疫苗和培育競爭性製造外包市場至關重要。

COVID-19 的影響：

COVID-19 大流行從多個方面對疫苗受託製造市場產生了重大影響。首先，疫苗生產服務需求空前激增，導致現有生產能力緊張，產生了產能擴張和產能提升的需求。其次，疫苗開發和分銷的緊迫性要求製藥公司和契約製造製造商之間進行合作，從而促進契約製造的成長。此外，對疫苗生產先進技術（例如 mRNA 技術）的關注為擁有專業知識的契約製造製造商創造了新的機會。

預計預測期內臨床領域規模最大

疫苗契約製造市場的臨床領域呈現穩定成長，疫苗開發和臨床試驗投資的增加帶動了契約製造服務的需求。此外，感染疾病和流行病的激增正在加速疫苗研究，並導致對製造能力的需求增加。此外，生物技術和免疫學的進步正在擴大疫苗開發的範圍，進一步推動該領域的成長。臨床部門處理早期臨床試驗，其中生產的速度和彈性至關重要，這使得製造外包成為製藥公司的重要合作夥伴。

生技公司領域預計在預測期內複合年成長率最高。

隨著生技公司擴大委託製造外包給專業受託製造廠商(CMO) 以專注於研發，生物技術領域正在經歷強勁成長。感染疾病爆發和持續的 COVID-19 大流行推動了對疫苗的需求，這推動了擴大生產能力的需求。生物技術的進步使得能夠開發出更複雜的疫苗，並且需要專門的製造技術。此外，CMO 提供的彈性和擴充性使生物技術公司能夠快速回應不斷變化的市場需求和監管要求。

比最大的地區

北美擁有先進的生物製藥基礎設施和專業知識，吸引企業委託疫苗製造，因此疫苗契約製造市場正在顯著成長。 COVID-19大流行加速了對疫苗生產能力的需求，促使製藥公司尋求受託製造服務，以快速回應全球需求。此外，監管支持和有利的政府措施正在為疫苗生產合作夥伴關係創造有利的環境。

複合年成長率最高的地區：

由於其製造基礎設施和熟練的勞動力，亞太地區正在經歷顯著的成長，使其成為外包疫苗生產的一個有吸引力的地區。有利的政府政策和激勵措施正在鼓勵跨國製藥公司在該地區設立生產設施。此外，由於人口成長和醫療保健意識的提高，對疫苗的需求不斷增加，正在刺激市場擴張。此外，COVID-19 大流行凸顯了疫苗生產能力的重要性，促使各國政府和企業投資擴大亞太地區的生產能力。

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球疫苗契約製造市場：依產品分類

  • 重組載體疫苗
  • 去活化疫苗
  • 類毒素疫苗
  • 合成疫苗
  • 聯合疫苗
  • 減毒疫苗
  • 基於次單元的疫苗
  • 基於 DNA 的疫苗
  • 其他產品

第6章全球疫苗契約製造市場：按類型

  • 細菌
  • 病毒性的
  • 其他類型

第7章 全球疫苗契約製造市場：依業務規模分類

  • 臨床
  • 商業的
  • 臨床前

第8章全球疫苗契約製造市場：依流程

  • 下游
  • 上游
  • 分隔器
  • 電解質
  • 其他工藝

第9章 全球疫苗契約製造市場：依應用分類

  • 對於動物
  • 對於人類
  • 其他用途

第10章全球疫苗契約製造市場：依最終用戶分類

  • 生技公司
  • 調查機構
  • 製藥公司
  • 其他最終用戶

第11章全球疫苗契約製造市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Catalent
  • Charles River Laboratories International Inc.
  • CJ CheilJedang Corporation
  • CSL Seqirus
  • Curia Global
  • Emergent BioSolutions Inc.
  • Fujifilm Holdings Corporation
  • Gedeon Richter（Richter-Helm BioLogics）
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma
  • Lonza Group AG
  • Merck KGaA
  • Recipharm AB
  • Samsung Biologics
  • WuXi Biologics
Product Code: SMRC25946

According to Stratistics MRC, the Global Vaccine Contract Manufacturing Market is accounted for $3.51 billion in 2023 and is expected to reach $8.30 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Vaccine contract manufacturing involves outsourcing the production of vaccines to third-party manufacturers. Pharmaceutical companies partner with contract manufacturing organizations (CMOs) to leverage their expertise, facilities, and resources for the efficient and scalable production of vaccines. This approach allows companies to focus on research, development, and marketing while ensuring timely and cost-effective manufacturing of vaccines. Contract manufacturers adhere to strict quality standards and regulatory requirements, providing assurance of safety and efficacy. This model enables flexibility in production capacity, accelerating the availability of vaccines to meet global demand, especially during pandemics or emergencies.

According to data published by the American Academy of Pediatrics in March 2022, more than 1 million people in the United States have long-term hepatitis B infections, and people who are infected with hepatitis B as a baby have a 90% chance of developing serious, chronic conditions like liver cancer in their lifetime.

Market Dynamics:

Driver:

Increasing demand for vaccines

The increasing demand for vaccines serves as a pivotal driver propelling the growth of the vaccine contract manufacturing market. As the global population continues to prioritize preventive healthcare measures, the need for efficient vaccine production escalates. Vaccine Contract Manufacturing offers pharmaceutical companies the flexibility to scale up production swiftly to meet this rising demand. Additionally, outsourcing manufacturing to specialized facilities enables companies to focus on research and development, accelerating vaccine innovation. Furthermore, partnerships with contract manufacturers streamline the production process, ensuring timely delivery of vaccines to the market.

Restraint:

Quality control challenges

Quality control challenges primarily stem from the need for strict adherence to regulatory standards, complex manufacturing processes, and the demand for high-volume production. Ensuring consistent product quality across various batches and facilities presents a significant hurdle. Additionally, the global distribution of manufacturing sites complicates standardization and oversight. Moreover, the urgency to meet production deadlines while maintaining stringent quality standards can lead to errors or oversights. Variability in raw materials and equipment further exacerbates these challenges.

Opportunity:

Global vaccine demand

The global vaccine contract manufacturing market presents a significant opportunity driven by the escalating demand for vaccines worldwide. With the advent of the COVID-19 pandemic and increased focus on vaccination, there's a pressing need for expanded production capacity. This market offers advantages such as flexibility, scalability, and cost-effectiveness, enabling swift responses to emerging infectious diseases and large-scale immunization campaigns. Outsourcing vaccine production mitigates the risks associated with in-house manufacturing, including regulatory compliance and resource allocation.

Threat:

Intellectual property issues

Many vaccines are protected by patents, trademarks, and trade secrets, limiting access to their production methods and technologies. This creates barriers for contract manufacturers seeking to enter the market or scale up production. Additionally, disputes over IP rights can lead to legal battles, delays, and increased costs for manufacturers. Lack of clarity or enforcement of IP laws can also discourage innovation and investment in new vaccine manufacturing technologies. Addressing these issues through clear licensing agreements and effective IP protection mechanisms is crucial for ensuring equitable access to vaccines and fostering a competitive contract manufacturing market.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the vaccine contract manufacturing market in several ways. Firstly, there was an unprecedented surge in demand for vaccine manufacturing services, leading to a strain on existing capacities and prompting the need for expansion and ramping up of production capabilities. Secondly, the urgency of vaccine development and distribution necessitated collaborations between pharmaceutical companies and contract manufacturers, driving growth in the contract manufacturing sector. Additionally, the focus on advanced technologies for vaccine production, such as mRNA technology, created new opportunities for contract manufacturers with specialized expertise.

The clinical segment is expected to be the largest during the forecast period

The clinical segment in the vaccine contract manufacturing market is witnessing robust growth due to increasing investments in vaccine development and clinical trials are driving demand for contract manufacturing services. Additionally, the surge in infectious diseases and pandemics has accelerated vaccine research, leading to a higher demand for manufacturing capacity. Moreover, advancements in biotechnology and immunology have widened the scope of vaccine development, further fueling growth in this segment. The clinical segment caters to early-stage trials, where speed and flexibility in manufacturing are crucial, making contract manufacturers' indispensable partners for pharmaceutical companies.

The biotech companies segment is expected to have the highest CAGR during the forecast period

The Biotech Companies segment is experiencing robust growth because biotech firms are increasingly outsourcing manufacturing to specialized contract manufacturing organizations (CMOs) to focus on research and development. The demand for vaccines, driven by infectious disease outbreaks and the ongoing COVID-19 pandemic, is driving the need for expanded manufacturing capacity. Advancements in biotechnology are enabling the development of more complex vaccines, necessitating specialized manufacturing expertise. Additionally, the flexibility and scalability offered by CMOs allow biotech companies to respond quickly to changing market demands and regulatory requirements.

Region with largest share:

North America has witnessed significant growth in the vaccine contract manufacturing market due to the region's boasting advanced biopharmaceutical infrastructure and expertise, attracting companies to outsource vaccine production. The COVID-19 pandemic has accelerated demand for vaccine manufacturing capabilities, prompting pharmaceutical firms to seek contract manufacturing services to meet global needs swiftly. Additionally, regulatory support and favourable government initiatives have fostered a conducive environment for vaccine manufacturing partnerships.

Region with highest CAGR:

The Asia-Pacific region has experienced significant growth due to the region manufacturing infrastructure coupled with a skilled workforce, making it an attractive destination for vaccine production outsourcing. Favourable government policies and incentives have encouraged multinational pharmaceutical companies to establish manufacturing facilities in the region. Moreover, the increasing demand for vaccines, driven by population growth and rising healthcare awareness, has further fueled market expansion. Furthermore, the COVID-19 pandemic has highlighted the importance of vaccine manufacturing capacity, prompting governments and companies to invest in expanding production capabilities in the Asia Pacific.

Key players in the market

Some of the key players in Vaccine Contract Manufacturing market include AGC Biologics, Ajinomoto Bio-Pharma Services, Catalent, Charles River Laboratories International Inc., CJ CheilJedang Corporation, CSL Seqirus, Curia Global, Emergent BioSolutions Inc., Fujifilm Holdings Corporation , Gedeon Richter (Richter-Helm BioLogics) , ICON PLC, IDT Biologika GmbH, KBI Biopharma, Lonza Group AG, Merck KGaA, Recipharm AB, Samsung Biologics and WuXi Biologics.

Key Developments:

In April 2024, Invenra Inc., an innovative leader in bispecific antibody technology, has announced a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.

In April 2024, Merck has launched the Aptegra CHO Genetic Stability Assay, which leverages whole-genome sequencing and bioinformatics to significantly accelerate customers' biopharmaceutical safety testing, thereby helping to accelerate customers' entry into commercial production.

Products Covered:

  • Recombinant Vector Vaccines
  • Inactivated Vaccines
  • Toxoid-based Vaccines
  • Synthetic Vaccines
  • Conjugate Vaccines
  • Attenuated Vaccines
  • Subunit-based Vaccines
  • DNA-based Vaccines
  • Other Products

Types Covered:

Bacterial

Viral

Other Types

Scale of Operations Covered:

  • Clinical
  • Commercial
  • Preclinical

Processes Covered:

  • Downstream
  • Upstream
  • Separator
  • Electrolyte
  • Other Processes

Application Covered:

  • Veterinary
  • Human Use
  • Other Applications

End Users Covered:

  • Biotech Companies
  • Research Institutes
  • Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccine Contract Manufacturing Market, By Product

  • 5.1 Introduction
  • 5.2 Recombinant Vector Vaccines
  • 5.3 Inactivated Vaccines
  • 5.4 Toxoid-based Vaccines
  • 5.5 Synthetic Vaccines
  • 5.6 Conjugate Vaccines
  • 5.7 Attenuated Vaccines
  • 5.8 Subunit-based Vaccines
  • 5.9 DNA-based Vaccines
  • 5.10 Other Products

6 Global Vaccine Contract Manufacturing Market, By Type

  • 6.1 Introduction
  • 6.2 Bacterial
  • 6.3 Viral
  • 6.4 Other Types

7 Global Vaccine Contract Manufacturing Market, By Scale of Operations

  • 7.1 Introduction
  • 7.2 Clinical
  • 7.3 Commercial
  • 7.4 Preclinical

8 Global Vaccine Contract Manufacturing Market, By Process

  • 8.1 Introduction
  • 8.2 Downstream
    • 8.2.1 Analytical and QC Studies
    • 8.2.2 Fill and Finish
    • 8.2.3 Packaging
    • 8.2.4 Other Downstream Processes
  • 8.3 Upstream
    • 8.3.1 Bacterial Expression Systems
    • 8.3.2 Baculovirus/Insect Expression Systems
    • 8.3.3 Mammalian Expression Systems
    • 8.3.4 Yeast Expression Systems
    • 8.3.5 Other Upstream Processes
  • 8.4 Separator
  • 8.5 Electrolyte
  • 8.6 Other Processes

9 Global Vaccine Contract Manufacturing Market, By Application

  • 9.1 Introduction
  • 9.2 Veterinary
  • 9.3 Human Use
  • 9.4 Other Applications

10 Global Vaccine Contract Manufacturing Market, By End User

  • 10.1 Introduction
  • 10.2 Biotech Companies
  • 10.3 Research Institutes
  • 10.4 Pharmaceutical Companies
  • 10.5 Other End Users

11 Global Vaccine Contract Manufacturing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AGC Biologics
  • 13.2 Ajinomoto Bio-Pharma Services
  • 13.3 Catalent
  • 13.4 Charles River Laboratories International Inc.
  • 13.5 CJ CheilJedang Corporation
  • 13.6 CSL Seqirus
  • 13.7 Curia Global
  • 13.8 Emergent BioSolutions Inc.
  • 13.9 Fujifilm Holdings Corporation
  • 13.10 Gedeon Richter (Richter-Helm BioLogics)
  • 13.11 ICON PLC
  • 13.12 IDT Biologika GmbH
  • 13.13 KBI Biopharma
  • 13.14 Lonza Group AG
  • 13.15 Merck KGaA
  • 13.16 Recipharm AB
  • 13.17 Samsung Biologics
  • 13.18 WuXi Biologics

List of Tables

  • Table 1 Global Vaccine Contract Manufacturing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Vaccine Contract Manufacturing Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Vaccine Contract Manufacturing Market Outlook, By Recombinant Vector Vaccines (2021-2030) ($MN)
  • Table 4 Global Vaccine Contract Manufacturing Market Outlook, By Inactivated Vaccines (2021-2030) ($MN)
  • Table 5 Global Vaccine Contract Manufacturing Market Outlook, By Toxoid-based Vaccines (2021-2030) ($MN)
  • Table 6 Global Vaccine Contract Manufacturing Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 7 Global Vaccine Contract Manufacturing Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 8 Global Vaccine Contract Manufacturing Market Outlook, By Attenuated Vaccines (2021-2030) ($MN)
  • Table 9 Global Vaccine Contract Manufacturing Market Outlook, By Subunit-based Vaccines (2021-2030) ($MN)
  • Table 10 Global Vaccine Contract Manufacturing Market Outlook, By DNA-based Vaccines (2021-2030) ($MN)
  • Table 11 Global Vaccine Contract Manufacturing Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 12 Global Vaccine Contract Manufacturing Market Outlook, By Type (2021-2030) ($MN)
  • Table 13 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial (2021-2030) ($MN)
  • Table 14 Global Vaccine Contract Manufacturing Market Outlook, By Viral (2021-2030) ($MN)
  • Table 15 Global Vaccine Contract Manufacturing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 16 Global Vaccine Contract Manufacturing Market Outlook, By Scale of Operations (2021-2030) ($MN)
  • Table 17 Global Vaccine Contract Manufacturing Market Outlook, By Clinical (2021-2030) ($MN)
  • Table 18 Global Vaccine Contract Manufacturing Market Outlook, By Commercial (2021-2030) ($MN)
  • Table 19 Global Vaccine Contract Manufacturing Market Outlook, By Preclinical (2021-2030) ($MN)
  • Table 20 Global Vaccine Contract Manufacturing Market Outlook, By Process (2021-2030) ($MN)
  • Table 21 Global Vaccine Contract Manufacturing Market Outlook, By Downstream (2021-2030) ($MN)
  • Table 22 Global Vaccine Contract Manufacturing Market Outlook, By Analytical and QC Studies (2021-2030) ($MN)
  • Table 23 Global Vaccine Contract Manufacturing Market Outlook, By Fill and Finish (2021-2030) ($MN)
  • Table 24 Global Vaccine Contract Manufacturing Market Outlook, By Packaging (2021-2030) ($MN)
  • Table 25 Global Vaccine Contract Manufacturing Market Outlook, By Other Downstream Processes (2021-2030) ($MN)
  • Table 26 Global Vaccine Contract Manufacturing Market Outlook, By Upstream (2021-2030) ($MN)
  • Table 27 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial Expression Systems (2021-2030) ($MN)
  • Table 28 Global Vaccine Contract Manufacturing Market Outlook, By Baculovirus/Insect Expression Systems (2021-2030) ($MN)
  • Table 29 Global Vaccine Contract Manufacturing Market Outlook, By Mammalian Expression Systems (2021-2030) ($MN)
  • Table 30 Global Vaccine Contract Manufacturing Market Outlook, By Yeast Expression Systems (2021-2030) ($MN)
  • Table 31 Global Vaccine Contract Manufacturing Market Outlook, By Other Upstream Processes (2021-2030) ($MN)
  • Table 32 Global Vaccine Contract Manufacturing Market Outlook, By Separator (2021-2030) ($MN)
  • Table 33 Global Vaccine Contract Manufacturing Market Outlook, By Electrolyte (2021-2030) ($MN)
  • Table 34 Global Vaccine Contract Manufacturing Market Outlook, By Other Processes (2021-2030) ($MN)
  • Table 35 Global Vaccine Contract Manufacturing Market Outlook, By Application (2021-2030) ($MN)
  • Table 36 Global Vaccine Contract Manufacturing Market Outlook, By Veterinary (2021-2030) ($MN)
  • Table 37 Global Vaccine Contract Manufacturing Market Outlook, By Human Use (2021-2030) ($MN)
  • Table 38 Global Vaccine Contract Manufacturing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 39 Global Vaccine Contract Manufacturing Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 Global Vaccine Contract Manufacturing Market Outlook, By Biotech Companies (2021-2030) ($MN)
  • Table 41 Global Vaccine Contract Manufacturing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 42 Global Vaccine Contract Manufacturing Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 43 Global Vaccine Contract Manufacturing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.